Herein, we present the final analysis of a phase 1 trial (NCT00390299) that evaluated the maximum tolerated dose (MTD), safety and toxicity, as well as the preliminary efficacy of MV-CEA when administered intratumorally and into the resection cavity of patients with recurrent GBM. Here, CEACAM5 is linked to glioblastoma.